阿伐那非治疗勃起功能障碍的研究

目的应用Meta分析评价阿伐那非治疗勃起功能障碍的临床疗效和安全性。方法检索国内外有关比较阿伐那非和安慰剂用于治疗勃起功能障碍的随机对照试验，由两名评价员独立按Cochrane系统评价方法对文献进行质量评价和提取资料后，采用RevMan 5．2统计软件进行Meta分析。结果共纳入4个随机对照试验。结果显示，经过12周治疗后，阿伐那非治疗组可以提高患者的国际勃起功能指数5评分（MD=d．92，95％CI：4．12-5．72，P=0．000），性生活日记2（RR=3．40，95％CI：2．66-4．34，P=0．000），性生活日记3（RR=2．61，95％CI：2．19-3．11，P=0．000），但阿伐那非治疗组的药物不良反应发生率较安慰剂组高。结论阿伐那非治疗组可以明显提高患者的勃起功能，有望成为治疗勃起功能障碍的新选择。由于文献纳入的较少，需要更多大样本的随机对照试验进一步证实。

Efficacy and Safety of Avanafil in the Treatment of Erectile Dysfunction.

Objective To compare the efficacy and safety of avanafil for the treatment of erectile dysfunction（ED） through a system- atic review. Methods All randomized controlled trials of avanafil and placebo in the treatment of erectile dysfunction were collected. The quality of included trials was assessed. Relevant data were selected according to the standard of Cochrane systematic review by two review- ers. The statistical software Revman 5.2 was used for Meta analysis. Results A total of four randomized controlled trials were included in this meta- analysis. Avanafil was found to be more effective than placebo,and the tolerability was good. The pooled results showed that after 12 weeks treatment, avanafil was better than placebo group in change from baseline for International Index of Erectile Function score at follow - up endpoint （ MD = 4.92, 95% CI ： 4.12 - 5.72, P 〈 0. 00001 ） , in the change from baseline for Sexual Encounter Profile 2 （RR = 3.40, 95% CI： 2.66 - 4.34, P 〈 0. 00001 ） and in the change from baseline for Sexual Encounter Profile questions 3 （ RR = 2.61 , 95% CI： 2.19 - 3.11 , P 〈 0. 00001 ）. However, the avanafil had more adverse reaction. Conclusion The current meta - analysis suggested that avanafil is an effective and well - tolerated drug for men with ED, and thus has the potential to be an attractive option for the treatment of ED. Because of few studies, more high quality randomized controlled trials with large samples are required to get further confirmation.